FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns treating haematological malignancies. That is ensured by administering a PI3-kinase inhibitor having the following structure:
or its pharmaceutically acceptable form. Compound is administered orally in amount of 25 mg twice a day.
EFFECT: it provides effective treatment combined with minimal side effects due to high inhibitory activity of the given compound with respect to PI3-kinases.
18 cl, 38 dwg, 26 ex, 20 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING MALIGNANT TUMORS USING PIZ-KINASE ISOFORM MODULATORS | 2014 |
|
RU2705204C2 |
| BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
| COMBINATION THERAPY | 2017 |
|
RU2754507C2 |
| USING SMOOTHENED ANTAGONISTS FOR TREATING HEDGEHOG PATHWAY RELATED DISORDERS | 2009 |
|
RU2519200C2 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| COMBINATION OF PIK3 INHIBITOR AND INHIBITOR C-MET | 2013 |
|
RU2705095C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| SOME CHEMICAL STRUCTURES, COMPOSITIONS AND METHODS | 2009 |
|
RU2513636C2 |
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
